Menu
1 min read · estimated
APPROVED USE
What FDA approved
For adults with refractory anaplastic astrocytoma. The revised indication removed the previous requirement for progression on nitrosourea and procarbazine treatment.
LAMPGEN ANALYSIS
Why it matters
The revised label removed an older prior-treatment constraint for refractory disease.
What research teams should watch
Apply the historical label version when auditing whether earlier therapy was required.
PRIMARY RECORDS